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Abstract 
Background: Hypoxia is known to be prevalent in solid tumors such as non-small cell lung cancer (NSCLC) and 
reportedly correlates with poor prognostic clinical outcome. PET imaging can provide in-vivo hypoxia measurements 
to support targeted radiotherapy treatment planning. We explore the potential of proton therapy in performing 
patient-specific dose escalation and compare it with photon volumetric modulated arc therapy (VMAT).
Methods: Dose escalation has been calibrated to the patient specific tumor response of ten stage IIb-IIIb NSCLC 
patients by combining HX4-PET imaging and radiobiological modelling of oxygen enhancement ratio (OER) to target 
variable tumor hypoxia. In a dose-escalation-by-contour approach, escalated dose levels were simulated to the most 
hypoxic region of the primary target and its effectiveness in improving loco-regional tumor control was assessed. Fur-
thermore, the impact on normal tissue of proton treatments including dose escalation was evaluated in comparison 
to the normal tissue complication probability (NTCP) of conventional VMAT plans.
Results: Ignoring regions of tumor hypoxia can cause overestimation of TCP values by up to 10%, which can effec-
tively be recovered on average to within 0.9% of the nominal TCP, using patient-specific dose escalations of up to 22% 
of the prescribed dose to PET defined hypoxic regions. Despite such dose escalations, the use of protons could also 
simultaneously reduce mean doses to the heart (− 14.3  GyRBE), lung (− 8.3  GyRBE), esophagus (− 6.9  GyRBE) and spinal 
cord (− 3.8 Gy) compared to non-escalated VMAT plans. These reductions are predicted to lead to clinically relevant 
decreases in NTCP for radiation-induced pneumonitis (− 11.3%), high grade heart toxicity (− 7.4%) and esophagitis 
(− 7.5%).
Conclusions: This study suggests that the administration of proton therapy for dose escalation to patient specific 
regions of tumor hypoxia in the treatment of NSCLC can mitigate TCP reduction due to hypoxia-induced radio resist-
ance, while simultaneously reducing NTCP levels even when compared to non-escalated treatments delivered with 
state-of-the-art photon techniques.
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Background
Lung cancer is the most common type of cancer world-
wide, with more than 2 million new cases a year and 
almost 1.8 million deaths [1]. Of these, 80% are non-
small cell lung cancer (NSCLC) patients [2], typically 
treated with surgery and adjuvant treatment if needed or 
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a combination of radio- and chemotherapy for advanced 
stages of disease. Hypoxia is known to be prevalent in 
large solid tumors and reportedly correlated with poor 
prognostic outcome [3], therefore assessment of hypoxia 
using PET imaging could be of great value in the manage-
ment of NSCLC [4, 5]. Even though PET tracers, such as 
F-MISO, F-FAZA or F-HX4 have a demonstrated sensi-
tivity to tissue oxygenation [6], hypoxia imaging is rarely 
part of radiotherapy routine imaging. That is partly due 
to the uncertainty in quantitative assessment and repro-
ducibility of imaging biomarkers, but also due to the lack 
of standardized care pathways capable of making use of 
such additional information. A way to overcome hypoxia 
is dose escalation, an approach that has been tested 
in a few randomized trials, including NSCLC patients 
cohorts [7], albeit with questionable success. Photon 
therapy, as shown in the seminal RTOG 0617 trial [7], 
however might not be particularly suited for precise 
dose painting as required for hypoxia targeting, as the 
increase in integral dose in normal tissues increases the 
risk of toxicity. As such, proton therapy could be a bet-
ter alternative, with dosimetric benefits for lung cancer 
treatments regarding normal tissue toxicity [8] as well as 
promising clinical results [9, 10] although the MDACC 
trial questioned the clinical benefit of protons delivered 
with a passive delivery paradigm with no motion-mitiga-
tion strategy other than increasing tumor margins [11]. 
A phase III trial (RTOG 1308; NCT01993810) [12] has 
randomized 2/3 of the accrual target and should give 
an answer to the value of protons for the treatment of 
these challenging patients. Moreover, image guidance 
[13] and motion management technologies [14] in pen-
cil beam scanning (PBS) are continuously being refined 
and nowadays provide the technical background for the 
locoregional irradiation of hypoxic volumes of the tumor 
even in the presence of organ motion, should it be proven 
beneficial in terms of tumor control. However, to our 
knowledge, the potential for proton therapy treatments 
that include locally boosting hypoxic regions of NSCLC 
tumors has not yet been studied.
In this work we have explored a straight-forward 
approach to integrate hypoxia imaging in proton ther-
apy planning as the basis to calibrate dose escalation for 
patient specific tumor response. We wished to evalu-
ate the potential of proton therapy for such a treatment 
approach at different clinical levels assessing (i) what the 
effect of the proposed dose escalation strategy on tumor 
control probability (TCP) is, taking into account hypoxia-
induced radio resistance and (ii) how doses to organs-at-
risk (OARs) and the resulting normal tissue complication 
probabilities (NTCP) are affected by proton dose esca-
lation compared to state-of-the-art photon treatments. 
We answered these questions by evaluating comparative 
treatments of 10 advanced-stage NSCLC patients to esti-
mate potential benefits of proton therapy in the context 
of hypoxia-targeted dose escalation using TCP and a 
range of different NTCP models.
Methods
Patient data
Ten stage IIb-IIIb NSCLC patients with hypoxic vol-
umes in the primary target have been selected from 
an ongoing phase II randomized clinical trial cohort 
(NCT01024829). The dataset, which is made freely avail-
able by Even et al. [15], includes for each patient the mid-
ventilation planning CT with clinical structures drawn 
by experienced radio-oncologists, together with a HX4 
PET image and associated low-dose CT obtained within 
a week of the planning CT acquisition. Relevant details 
of this cohort, including patient sex, age and tumor char-
acteristics are summarized in Table 1. Patients with stage 
III upwards received concurrent chemotherapy.
Treatment planning
For each patient, a conventional photon volumetric 
modulated arc therapy (VMAT) and pencil beam scan-
ning proton (PBSPT) treatment were planned according 
to the criteria of the RTOG 1308 phase III randomized 
trial (NCT01993810) comparing photon vs. proton 
chemoradiotherapy for stage II-IIIb NSCLC patients. 
An overview of the planning constraints following the 
amendments from March 2018 is given in the Additional 
file 1: Supplementary Material S1. Nominal prescription 
dose to the planning target volume (PTV) is 70  GyRBE, 
with the option to reduce it to 60  GyRBE should normal 
tissue constraints not be met. Patients undergo radia-
tion therapy 5  days per week for a total of 35 fractions 
at 2  GyRBE per fraction. Primary gross tumor volumes 
Table 1 Clinical characteristics of the patients included in this 
study
Patient # Sex Age (years) cTNM UICC Stage GTV Volume 
(total (primary)) 
[cc]
1 M 66 T2N3M0 IIIb 95.2 (78.6)
2 F 46 T2N2M0 IIIa 191.1 (169.5)
3 M 65 T3N2M0 IIIa 190.1 (148.8)
4 M 64 T4N2M0 IIIb 230.2 (214.3)
5 F 65 T2N2M0 IIIa 86 (32.8)
6 M 66 T3N2M0 IIIa 107.4 (95.3)
7 M 60 T4N1M0 IIIb 862.4 (853.6)
8 M 71 T2N3M0 IIIb 97.3 (42.8)
9 M 77 T3N2M0 IIIa 304.9 (296.3)
10 M 82 T3N0M0 IIb 63.3 (63.3)
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 (GTVprim; Table 1) and lymph nodes  (GTVlnx) from Even 
et al. [15] were drawn on the mid-ventilation phase of a 
4D FDG-PET/CT and expanded isotropically by 5 mm to 
create the clinical target volumes  CTVprim and  CTVInx. 
A uniform 5 mm PTV margin was applied to the lymph 
nodes. Our retrospective analysis of the primary target 
structures indicated that a CTV to PTV margin of the 
order of 10  mm was adjusted on a patient-by-patient 
basis accounting for breathing motion. The considered 
organs at risk (OARs) were the esophagus, spinal cord, 
heart, brachial plexus, as well as both lungs excluding the 
GTVs.
VMAT treatments were planned with RapidArc 
(Eclipse version 13, Varian Medical Systems, Palo Alto, 
CA, USA) with 2–3 full arcs for medial tumors and half 
arcs for the more lateral ones, using standard 6 MV 
machine data for a Varian True Beam. For the proton 
plans, an in-house treatment planning system (PSIPlan 
[16]) has been used to simulate proton treatments using 
beam data from Gantry 2 at our institute. Posterior or 
anterior beam arrangements were favored, with 3 fields 
individually optimized in single field optimization (SFO) 
mode using an RBE of 1.1 [17], which is standard practice 
in our clinical planning. An experienced treatment plan-
ner (NB) for both VMAT and PBSPT has reviewed and 
approved all the plans used in this study. Note, hypoxia 
guided dose escalation was performed only for the pro-
ton plans, as even without dose-escalation, all VMAT 
plans were close to the specified dose constraints, and 
dose escalation could not be performed without violating 
these.
Hypoxia‑guided dose escalation
In addition to standard photon and proton treatment 
plans, for each patient a dose escalated plan was created 
for proton therapy. HX4 PET hypoxia images were used 
in combination with calibrated oxygen enhancement 
ratio (OER) models to plan a localized dose boost to a 
sub-volume of the GTV. For each patient, the hypoxic 
region within the primary tumor  (GTVhypoxic) was iden-
tified on PET images including the set of voxels with a 
tumor-to-background HX4 uptake ratio above 1.4 with 
respect to the aortic arch [15]. HX4 PET data were fused 
with the mid-ventilation planning CT via rigid registra-
tion of the low-dose CT associated with the PET acqui-
sition. A first rough alignment of the bony anatomy was 
further refined with automatic registration using a region 
of interest on the primary target (Velocity 4.1, Varian, 
Palo Alto, CA, USA) and the resulting transformation 
used to propagate the  GTVhypoxic structure onto the plan-
ning images. Finally, to optimize dose homogeneity inside 
the  GTVhypoxic, the structure was expanded by 3 mm in 
the planning process. Afterwards, PET standardized 
uptake was converted into partial oxygen pressure  (pO2) 
following a HX4 to  pO2 calibration from Ureba et al. [18] 
and based on that the OER calculated using the proton 
specific model proposed by Dahle et  al. [19]. This con-
version requires a definition of normoxic partial oxygen 
pressure, for which we have considered 30 mmHg. A uni-
form dose escalation factor (DE) for  GTVhypoxic was then 
defined as:
where OERNSCLC is an average value for NSCLC tumors 
which have an estimated mean  pO2 equal to 16.4 mmHg 
[20]. This corresponds to a mean OER of 1.05, which is 
assumed to be accounted for in the treatment proto-
col and empirical definition of the prescription dose. 
 OERhypoxic is the OER in the hypoxic region of the tumor 
calculated based on the mean HX4 PET standardize 
uptake value (SUV) in the structure. At this stage, the 
OER was calculated with a constant proton linear energy 
transfer (LET) of 2  keV/µm, thus allowing optimization 
of plans in a wide range of clinical treatment planning 
systems that, most often, do not yet include sophisticated 
LET-based modelling. However, the implications of this 
assumption on tumor control are assessed by consider-
ing variable dose-averaged LET  (LETd) in our evaluation 
of the results. Following the DE determination, a ‘dose-
painting by contour’ approach was chosen to re-optimize 
the treatment plans for dose escalation, boosting the 
prescription dose (simultaneous integrated boost) to the 
 GTVhypoxic by the individual DE factor calculated for each 
patient in this volume. The same planning constraints as 
in the conventional plans were used with the addition of 
 V70 Gy*DE = 100% to  GTVhypoxic.
Estimation of tumor control
In order to estimate the effectiveness of dose escalation 
on tumor control, we compared tumor control prob-
ability (TCP) resulting from conventional and dose esca-
lated proton plans. The probability of local tumor control 
was estimated according to an equivalent uniform dose 
(EUD)-based model [21] using a parametrization built on 
data from Okunieff et al. [22] which was developed on a 
multi-institutional cohort of NSCLC patients. Both voxel 
level evaluation as well as overall TCP for primary CTV 
were calculated using the EUD with volume parameter 
a = −  10 [23]. Reference TCP estimates of conventional 
and dose-escalated treatments calculated without knowl-
edge of tissue oxygenation were reassessed account-
ing for the tumour OER of individual patients. Again, a 
baseline OER of 1.05 was assumed within the  GTVhypoxic. 
Unlike in planning, however, voxel-wise dose-weighted 
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the dose distributions and assessment of TCP. With the 
primary intent of understanding the effects of hypoxia in 
different planning strategy scenarios we decoupled OER 
and RBE calculations by assuming a constant RBE of 1.1, 
while adapting the OER inside the primary target based 
on local oxygenation and variable  LETd (similarly to what 
was proposed in Dahle et  al. [19]). Physical doses were 
transformed to  RBE1.1-weighted doses and then, scaled 
by the OER inside the PTV prior to EUD calculation. 
This procedure, requiring voxel level information, has 
required the resampling of dose data and PET images to 
the resolution of the planning CT for which we have used 
trilinear interpolation (Velocity 4.1, Varian, Palo Alto, 
CA, USA).
Estimation of normal tissue complication
The potential increase in healthy tissue toxicity due to 
dose escalation was assessed by comparing NTCP esti-
mates with conventional, non-escalated photon therapy 
treatments for radiation pneumonitis [24, 25], radiation-
induced esophagitis [26–28] and death due to heart 
failure [29]. In selecting the models, focus was put on 
externally validated models built on NSCLC cohorts. To 
avoid compromising the estimation of toxicity and thus 
our conclusions with the choice of organ architecture 
(serial/parallel), multiple models for pneumonitis and 
esophagitis were considered, providing results for vari-
ous hypotheses. An overview of the employed models is 
given in Table 2. For more details the reader is referred 
to the Additional file  1: Supplementary Material S2. As 
the healthy tissue around the tumor was most likely 
not subject to abnormal oxygen level, photon dose and 
 RBE1.1-weighted proton dose were used for NTCP cal-
culations. Data analysis and statistical testing was per-
formed in MATLAB (v2018b, The MathWorks, Natick, 
MA, USA). Statistical significance threshold was set to 
0.05.
Results
Treatment plans, hypoxia and LET
All patients have been successfully planned to RTOG 
1308 standard although prescription dose for patients 
1 and 8 (20% of the cohort) had to be reduced to 60 Gy 
in order to meet the lung constraints for the photon 
plans. To keep the plans normalized to target coverage, 
proton prescriptions for these two patients were simi-
larly reduced to 60  Gy, even though 70  Gy could have 
been achieved within constraints. A gallery of dose 
distributions with photon, proton and dose escalated 
proton plans for exemplary cases can be found in the 
Additional file  1: Supplementary Material S3. The over-
view of prescription dose, volume of the hypoxic struc-
ture  GTVhypoxic,  LETd,  pO2 as well as OER estimations 
within and outside of the hypoxic tumor volume for each 
patient is given in Table 3. DE factors ranged from 1.07 
to 1.22 (median, 1.12) for boost volumes between 5.2 
and 58.9  cc (median, 30.4). The boost factor is system-
atically lower than the estimated OER in the hypoxic 
region (median 1.16) due to our assumption of a base-
line OER within  GTVhypoxic reducing the need of dose 
escalation by about 5%. Median partial oxygen pressure 
in the hypoxic volume was in the 5 to 9.2 mmHg range 
(median 6.95 mmHg) and between 28 and 30 mmHg in 
the volume of the primary CTV that was not considered 
to be hypoxic.  LETd calculations showed median  LETd 
values between 1.9 and 2.6  keV/µm (median 2.2) in the 
primary CTV for the dose escalated proton plans, which 
is only marginally higher than our assumption of a con-
stant 2 keV/µm used for the DE factor estimation.  LETd 
values in the target were negligibly lower (< 0.1 keV/µm) 
for the conventional proton plans compared to the dose 
escalated ones. Exemplary  LETd distributions and  LETd 
Table 2 Overview of applied TCP and NTCP models
One TCP and six NTCP models were chosen based on multi-institutional cohorts, external validation and treatment modality. LKB: Lyman-Kutcher-Burman model, 
EUD: Equivalent uniform dose model
Model Type Endpoint References
TCP EUD Tumor control Okunieff et al. [22], 
Chaikh and Balosso 
[23]
NTCP Sigmoid Symptomatic radiation pneumonitis Appelt et al. [24]
NTCP LKB Radiation pneumonitis (grade ≥ 2) Tucker et al. [25]
NTCP Logistic Severe acute esophagitis (grade ≥ 2) Huang et al. [26]
NTCP Logistic Acute esophageal toxicity (grade ≥ 2) Wijsman et al. [27]
NTCP LKB Radiation induced esophagitis (grade ≥ 2) Wang et al. [28]
NTCP Relative seriality Death due to heart failure Gagliardi et al. [29]
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differences between conventional and dose escalated pro-
ton plans can be found in the Additional file 1: Supple-
mentary Material S4.
Tumor control probability
TCP of conventional plans has been reassessed account-
ing for variable OER and the possible inclusion of dose 
escalation. Effective TCPs, calculated taking into account 
the increased OER due to hypoxia, were generally lower 
than their estimates neglecting the actual tissue oxygena-
tion. The amount of TCP reduction was primarily a func-
tion of the specific tumour hypoxia (Fig. 1 – Planned vs. 
Effective (uniform dose)) and ranged from 1.1% (mean 
 pO2 in  GTVhypoxic = 9  mmHg, patient 8), up to 9.5% 
(mean  pO2 = 4.4  mmHg, patient 6). Despite the large 
inter-subject variability, the TCP was overestimated 
in our cohort by an average of 3.85% when OER effects 
were neglected. This hypoxia-induced reduction in local 
control was however effectively compensated for by dose 
escalation, a strategy capable of narrowing the discrep-
ancy with the planned TCP down to 0.9% on average.
The impact of hypoxia on voxel-wise TCP is shown in 
Fig. 2 for the primary PTV of the patient with the most 
severe hypoxia (Patient 6, 22% dose escalation). As a con-
sequence of the homogeneous dose escalation approach, 
TCP was restored in the hypoxic region of the target 
(within the black contour) and improved beyond its ini-
tial value (OER = 1) in the surrounding tissues, included 
or in close proximity of the  GTVhypoxic planning margin.
Normal tissue toxicity
The positive impact of dose escalation on TCP has to 
be weighed against the increase of the risk of radiation-
induced toxicities. As such, the dose to organs at risk for 
the most unfavorable proton plans, those that included 
dose escalation, were compared with conventional pho-
ton treatments. Mean dose-volume histograms for lungs, 
heart and esophagus show significantly lower doses to 
OARs for proton treatments compared to the conven-
tional VMAT plans (Fig. 3). Substantial mean dose reduc-
tions for protons could be observed across the whole 
cohort simulating the whole treatment course: on aver-
age the heart received 14.3 Gy less dose, the lungs 8.3 Gy, 
the esophagus 6.9 Gy and the spinal cord 3.8 Gy. As can 
be furthermore seen in Fig. 3, the OAR constraints were 
Table 3 Overview over quantities related to the effect of hypoxia in the primary CTV and hypoxic volume for each patient
For  LETd, pO2 and OER values, the median is reported with the 25 and 75 percentiles indicated in brackets. While the normoxic part of the CTV resulted in an OER of 1, 
the decreased levels of oxygen within the  GTVhypoxic led to increased OER, thus higher amounts of dose necessary to control the tumour










pO2 in  CTVprim – 
 GTVhypoxic [mmHg]
OER in  GTVhypoxic OER in 
 CTVprim‑
GTVhypoxic
1 60 48.3 1.17 2.2 (2.0,2.4) 5.4 (4.5,6.6) 29.5 (12.9,30) 1.22 (1.18,1.27) 1.0 (1.0,1.08)
2 70 58.9 1.15 2.3 (2.2,2.6) 6.0 (5.3,6.9) 25.1 (11.9,30) 1.2 (1.17,1.23) 1.0 (1.0,1.08)
3 70 19.8 1.10 1.9 (1.6,2.3) 7.9 (7.0,8.7) 30.0 (23.3,30) 1.15 (1.13,1.17) 1.0 (1.0,1.02)
4 70 37.5 1.13 2.1 (1.9,2.4) 6.6 (6.0,7.2) 30.0 (15.7,30) 1.18 (1.16,1.2) 1.0 (1.0,1.05)
5 70 8.0 1.12 2.6 (2.4,2.9) 7.2 (6.1,8.4) 30.0 (19.0,30) 1.16 (1.13,1.2) 1.0 (1.0,1.03)
6 70 52 1.22 2.5 (2.0,3.0) 5.0 (3.5,6.4) 29.2 (14.3,30) 1.24 (1.19,1.34) 1.0 (1.0,1.06)
7 70 46.8 1.10 1.9 (1.7,2.1) 8.2 (6.8,9.3) 30.0 (30,30) 1.14 (1.12,1.17) 1.0 (1.0,1.0)
8 60 23.3 1.07 2.2 (2.0,2.4) 9.2 (8.3,10.5) 30.0 (30,30) 1.12 (1.1,1.14) 1.0 (1.0,1.0)
9 70 20.9 1.13 2.2 (1.9,2.6) 6.7 (6.2,7.2) 28.0 (12.7,30) 1.18 (1.16,1.19) 1.0 (1.0,1.07)
10 70 5.2 1.12 2.6 (2.2,3.2) 7.4 (6.3,8.4) 30.0 (19.9,30) 1.16 (1.13,1.19) 1.0 (1.0,1.03)
Cohort Median 70 30.4 1.13 2.2 7 30 1.17 1
Fig. 1 TCP for each patient in the cohort calculated for the primary 
CTV. Losses in TCP due to hypoxia are shown in the reduced effective 
TCPs for the uniform dose prescription proton plans. Escalating the 
dose restores the TCP to what was originally planned for. The loss 
in effective TCP for uniform dose plans compared to the initial plan 
was correlated to the degree of hypoxia in the  GTVhypoxic (grayscale 
colorbar)
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already challenging to be met with non-escalated photon 
treatments, while proton doses were considerably below 
the constraints (e.g. Lungs  V20 Gy < 37% or Heart  V30 
Gy < 50%).
The use of protons thereby permits dose escalation to 
a tumor sub-volume with limited to no impact on the 
surrounding organs, thus maintaining normal tissue 
benefits compared to photons. Figure  4 shows NTCP’s 
for non-escalated photon, non-escalated proton and 
dose escalated proton plans. All NTCP calculations pre-
dicted a significant reduction for proton dose escalation 
plans compared to conventional photon treatments with 
the exclusion of the Wang et  al. [28] radiation-induced 
esophagitis model, which instead of using the mean 
esophageal dose, considers the esophagus a more serial 
organ (n = 0.24, Additional file  1: Supplementary Mate-
rial  S2). Reducing the maximum dose to the esophagus 
is challenging independent of the modality due to its 
proximity to the target volume for these patients. On 
the other hand, the risk of radiation-induced pneumo-
nitis could on average (across all considered models) be 
reduced by 11.3%, the risk of patient death due to heart 
failure by 7.4% and the risk for esophagitis reduced by 
7.5%.
Fig. 2 Exemplary voxel-wise TCP calculation from Patient 6 for the conventional proton plan with uniform dose prescription (A,B) and 
patient-specific escalated dose (22%) to the hypoxic tumor volume (C). PTV contours in orange, the hypoxic region  GTVhypoxic in black. Taking 
into account hypoxia information and its influence on TCP, locoregional losses can be observed (B) compared to the planned TCP (A) where OER 
is assumed to be consistently 1 throughout the target. The dose escalation (C) counteracts the increased radioresistance caused by hypoxia by 
increasing the dose to the radioresistant area and thus recovers TCP
Fig. 3 Mean DVHs for heart, lungs and esophagus are shown for the whole cohort (solid lines) for conventional non-escalated VMAT plans and 
dose-escalated proton plans. Color bands represent the cohort 25th to 75th percentile. Reductions in dose with dose-escalated proton plans are 
clearly visible for all OARs, despite the increased dose to the target
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Discussion
In this study, we have investigated hypoxia-guided proton 
dose escalation in a cohort of locally advanced NSCLC 
patients. Based on our treatment simulations, an image-
guided and patient-specific dose escalation by contour 
strategy allows the mitigation of TCP that may be lost 
due to the increased radio resistance of hypoxic regions 
of the tumor. The additional doses to the target were not 
found to be detrimental to normal tissue sparing, in fact 
risks of side effects in OARs were significantly lower for 
proton treatments compared to state-of-the-art photon 
therapy (Fig. 4).
While it has been shown that increased doses to the tar-
get can lead to better tumor control in locally advanced 
NSCLC [30] patients, the RTOG 0617 trial results [7] 
have shown that it is essential to balance between esca-
lated dose levels and normal tissue burden. Furthermore, 
especially at the level of local control there still is a lack of 
strong clinical evidence that supports the use of PBS pro-
ton therapy despite clear dosimetric benefits for critical 
OARs. While RTOG 1308 will hopefully provide some 
insight on the photon vs. proton debate for conventional 
NSCLC treatment, in a scenario where dose escalation is 
necessary, the improved spatial selectivity of proton ther-
apy could still be leveraged to perform dose-escalation 
with high precision, while keeping dose to healthy tis-
sue low [31, 32]. As demonstrated in other studies, there 
is a clear limit to the amount of dose that can be esca-
lated with current state-of-the-art radiotherapy without 
impacting normal tissue, and proton treatments, taking 
advantage of lower integral dose, can theoretically push 
this limit significantly further. OAR sparing is indeed of 
particular concern in locally advanced NSCLC, as shown 
by the MDACC trial [33], in which often the primary tar-
get is located in the proximity of critical organs such as 
the heart, lungs or esophagus. Many studies have con-
sidered dose escalation before, however mostly focusing 
on uniformly boosting tumor dose either by an empirical 
amount or unconstrained escalation until normal tissue 
constraints are met [15]. In contrast, we have investigated 
localized and patient-specific dose escalation based on 
quantitative hypoxia information extracted from PET 
imaging. This could result in a reduction of excess dose to 
the tumor and, ultimately, in lower healthy tissue burden. 
In this study, we complemented the dosimetry evalua-
tion with OER-weighted TCP and NTCP models to esti-
mate the treatment outcome, thus assessing the clinical 
potential of such anticipated reductions of healthy tissue 
dose. While the model-based evaluation of dosimetry dif-
ferences between modalities and treatment techniques 
cannot replace clinical evidence from clinical trials, it can 
be used to estimate the potential clinical benefit that can 
be obtained by using proton therapy against alternative 
options. For example, a reduction of 10% in the modelled 
risk of pneumonitis, as observed for most patients in our 
cohort, would have been sufficient reason to consider 
proton therapy for these patients according to the Dutch 
model-based approach for grade 2 complications [34].
In order to tailor the dose prescription to each patient, 
the latest research results in PET imaging calibration 
and radiobiological modelling of OER were combined 
in a practical, but nonetheless patient-specific approach 
Fig. 4 Distribution of NTCP for homogeneous dose prescription photon (blue), proton (black) and dose escalated proton plans (red) of the whole 
cohort. Significant (Wilcoxon Signed Rank Test) NTCP reductions are observed for the dose-escalated proton plans in lungs, heart and esophagus 
(excluding the Wang et al. [28] model) compared to the photon plans. Dose escalated did not result in significant increases in NTCP compared to 
the homogeneous dose prescription proton plans
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for determining the dose-escalation factor to target vari-
able tumor hypoxia. This method is however affected by 
a certain degree of uncertainty, starting with the require-
ment of an accurate measurement of tumor oxygenation 
in-vivo. The conversion from HX4 PET image intensity 
to  pO2-levels has not been extensively studied yet and 
is therefore possibly prone to errors in absolute oxygen 
measurements. Furthermore, the higher sensitivity at low 
oxygen pressures when compared to F-MISO [18] helps 
discriminating the smallest gradients but also requires 
utmost accuracy in calibration before use for quantitative 
dose escalation. In an attempt to minimize the impact of 
these uncertainties we have defined the dose escalation 
from the mean SUV in the  GTVhypoxic rather than the 
maximal value. Similarly critical is the radiobiological 
modelling of OER from the measured tissue hypoxia for 
which we selected the formulation from Dahle et al.[19]. 
This parametrization was considered the most appropri-
ate for our study since it is based on a popular model for-
mulation from Wenzl and Wilkens [35] which has been 
reported to agree well with clinical studies (for photons 
however), and which was further parametrized on the 
basis of proton data [19].
The calculation of the DE factor from PET images 
is possible and, as we have shown in-silico, hypoxia-
induced radio-resistance could potentially be overcome 
using such an approach. Nevertheless, the TCP could not 
be completely recovered (Fig. 2C). This is due to the cho-
sen dose-escalation-by-contour planning strategy which 
does not follow the heterogeneous tissue response within 
the target and the DE definition from the mean intensity 
of the hypoxia PET images. However, the TCP could be 
further optimized by taking the median/maximum OER 
as DE factor if the OAR dose constraints allow or by 
designing more complex dose escalation strategies with 
multiple sub-volumes with different levels of dose esca-
lation. As an alternative to dose-painting-by-contour, 
dose-painting-by-numbers has also been proposed [36, 
37] for a finer level of dose adaptation at the image voxel 
resolution. However, due to the large uncertainties that 
affect planning, and considering the possibly impaired 
treatment precision due to breathing motion we consider, 
at least at the current stage of technology, dose-painting-
by-contour to be the more appropriate technique for lung 
treatments. A further advantage of this method is that 
standard treatment planning systems can plan for such 
a dose escalation, obviating the need for more sophisti-
cated optimizers. The dose-escalation strategy presented 
in this work, i.e. homogeneous dose escalation adapted to 
the patient-specific hypoxia within a tumor sub-volume, 
can then be realistically explored in any clinic.
Clearly, another limitation of our study is the fact that 
the effects of potential organ motion on the treatments 
have been ignored. Indeed, sensitivity to intra-fractional 
organ motion is of particular concern in PBS proton 
therapy due to interplay effect and range uncertainties. 
In this study, all fields were planned with large PTV mar-
gins accounting for the free-breathing target motion, 
beam angles selected such minimal density gradients are 
crossed and uniform DE prescriptions obtained using 
single field (SFO) rather than multiple field optimisa-
tion (MFO). Nevertheless, simulations have all been per-
formed on a stationary, mid-ventilation anatomy. This 
simplification has allowed to investigate the potential of 
proton therapy in the context of hypoxia dose painting 
without skewing the results towards a particular planning 
approach or motion mitigation technique that would 
likely be modality specific and possibly influenced by the 
beam delivery performance of a given facility. Necessar-
ily, a discussion has to follow to identify the best treat-
ment approach to preserve localized dose escalation 
under the condition of motion. As such, our results are 
presented as a best case scenario and, to some extent, 
may reflect the experience of treatments in breath hold 
or with very narrow gating windows. On a similar note, 
unsafe dose-escalation can indeed be harmful, and there-
fore image guidance and motion mitigation techniques 
may need to be re-evaluated taking into account the 
specific requirement of dose painting, beyond the cur-
rent photon vs. proton debate and trials. The technical 
realization however, including appropriate margins and 
motion mitigation to bring these benefits into fruition, 
goes beyond the present discussion.
Finally, we have compared dose distributions and cor-
responding NTCPs of dose-escalated proton plans with 
non-escalated uniform dose VMAT plans to evaluate pro-
ton therapy against state-of-the-art photon treatments at 
the level of normal tissue toxicity. Dose escalation with 
VMAT was not part of the detailed investigations, since 
photon planning for advanced stage NSCLC patients 
with large tumors in proximity to the mediastinum is 
already challenging for a prescription dose of 70  Gy, 
if normal tissue dose constraints are not to be violated, 
especially those for lung tissue. The mean DVHs for 
the VMAT plans in Fig. 3 show how for most plans the 
OAR constraints (Lung  V20Gy < 37% and  V5Gy < 60%) were 
barely fulfilled across the cohort. Escalating the dose to 
a tumor sub-volume with that modality would inevitably 
increase doses to the surrounding organs and thus com-
promise constraints. Moreover, in order to assess the 
toxicity that would potentially be associated with proton 
treatments, considering the most aggressive plans, i.e. 
including dose escalation, is the most sensible choice.
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Conclusions
We presented a clinical option to target patient-specific 
tumor hypoxia with dose escalation. In a cohort of ten 
patients with stage IIb-IIIc NSCLC, median partial oxy-
gen pressures in the most hypoxic region within the pri-
mary target ranged from 5 to 9.2  mmHg, leading to an 
overestimation of radiotherapy efficacy by up to 10% of 
TCP. Local control was effectively recovered on aver-
age within 0.9% of nominal TCP with a patient-specific 
dose escalation up to 22% of the prescribed dose. The 
increased sparing of normal tissues using proton therapy 
has the potential for such biologically guided treatments 
compared to the latest generation of photon treatments, 
reducing the risk of radiation-induced pneumonitis 
(11.3%), patient death due to heart failure (7.4%) and 
esophagitis (7.4%).
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